Evangelos Terpos to Bortezomib
This is a "connection" page, showing publications Evangelos Terpos has written about Bortezomib.
Connection Strength
2.318
-
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. Eur J Haematol. 2018 Jan; 100(1):10-19.
Score: 0.660
-
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 07; 178(1):61-71.
Score: 0.634
-
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Eur J Haematol. 2018 Oct; 101(4):556-565.
Score: 0.175
-
Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018 06; 11(6):463-469.
Score: 0.172
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 03 09; 8(3):31.
Score: 0.169
-
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
Score: 0.167
-
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
Score: 0.094
-
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019 12; 23(12):8010-8018.
Score: 0.047
-
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Ann Hematol. 2019 Jun; 98(6):1457-1466.
Score: 0.045
-
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):e401-e419.
Score: 0.043
-
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
Score: 0.039
-
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
Score: 0.039
-
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
Score: 0.034